Download presentation
Presentation is loading. Please wait.
1
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
2
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Disclosure Information<br />Relationships Relevant to this Session Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
3
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
CRYSTAL study design Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
4
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Background Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
5
RAS mutation analysis: BEAMing
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
6
RAS mutation analysis: BEAMing
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
7
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Study profile Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
8
Other RAS mutations: CRYSTAL
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
9
Other RAS mutations: first-line studies
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
10
Comparison of RAS subgroups: <br />efficacy
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
11
Baseline characteristics
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
12
Efficacy: RAS subgroups
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
13
Efficacy: RAS subgroups
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
14
Progression-free survival
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
15
Progression-free survival
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
16
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Overall survival Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
17
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Overall survival Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
18
Efficacy: RAS subgroups
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
19
Safety: grade 3/4 adverse events
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
20
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Conclusions Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
21
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Acknowledgments Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Similar presentations
![Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.](/34/8349925/big_thumb.jpg "Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.>")
